<SEC-DOCUMENT>0000078003-25-000052.txt : 20250227
<SEC-HEADER>0000078003-25-000052.hdr.sgml : 20250227
<ACCEPTANCE-DATETIME>20250227103933
ACCESSION NUMBER:		0000078003-25-000052
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250227
DATE AS OF CHANGE:		20250227

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Haleon plc
		CENTRAL INDEX KEY:			0001900304
		STANDARD INDUSTRIAL CLASSIFICATION:	PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-93722
		FILM NUMBER:		25674412

	BUSINESS ADDRESS:	
		STREET 1:		BUILDING 5, FIRST FLOOR
		STREET 2:		THE HEIGHTS
		CITY:			WEYBRIDGE
		STATE:			X0
		ZIP:			KT13 0NY
		BUSINESS PHONE:		44 1932 822000

	MAIL ADDRESS:	
		STREET 1:		BUILDING 5, FIRST FLOOR
		STREET 2:		THE HEIGHTS
		CITY:			WEYBRIDGE
		STATE:			X0
		ZIP:			KT13 0NY

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DRVW 2022 Ltd
		DATE OF NAME CHANGE:	20211217

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		66 HUDSON BOULEVARD EAST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001-2192
		BUSINESS PHONE:		2127332323

	MAIL ADDRESS:	
		STREET 1:		66 HUDSON BOULEVARD EAST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001-2192

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <!-- Generated by Workiva -->
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0000078003</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>13</amendmentNo>
      <securitiesClassTitle>Ordinary Shares, nominal value GBP0.01 per share</securitiesClassTitle>
      <dateOfEvent>02/25/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001900304</issuerCIK>
        <issuerCUSIP>405552100</issuerCUSIP>
        <issuerName>Haleon plc</issuerName>
        <address>
          <com:street1>Building 5, First Floor, The Heights</com:street1>
          <com:city>Weybridge, Surrey</com:city>
          <com:stateOrCountry>X0</com:stateOrCountry>
          <com:zipCode>KT13 0NY</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Margaret M. Madden, Esq.</personName>
          <personPhoneNum>212-733-2323</personPhoneNum>
          <personAddress>
            <com:street1>Pfizer Inc.</com:street1>
            <com:street2>66 Hudson Boulevard East</com:street2>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10001</com:zipCode>
          </personAddress>
        </notificationInfo>
        <notificationInfo>
          <personName>Jacob A. Kling, Esq.</personName>
          <personPhoneNum>212-403-1000</personPhoneNum>
          <personAddress>
            <com:street1>Wachtell, Lipton, Rosen &amp; Katz</com:street1>
            <com:street2>51 West 52nd Street</com:street2>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10019</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0000078003</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Pfizer Inc.</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>661709764.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>661709764.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>661709764.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>7.3</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
        <commentContent>661,709,764 Ordinary Shares includes: (1) 661,709,764 Ordinary Shares, nominal value GBP0.01 per share ("Ordinary Shares"), of Haleon plc (the "Issuer"), held on behalf of Pfizer Inc. ("Pfizer" or the "Reporting Person") by Pfizer's nominee and (2) zero American Depositary Shares.  See Item 5.

Percent of class represented by amount in row (11) is calculated based upon 9,054,145,714 Ordinary Shares outstanding as of January 31, 2025, as reported by the Issuer on its Form 6-K filed with the Securities and Exchange Commission (the "SEC") on February 3, 2025.

The CUSIP on the cover page applies to the Issuer's American Depositary Shares, each representing two Ordinary Shares. No CUSIP has been assigned to the Ordinary Shares.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Ordinary Shares, nominal value GBP0.01 per share</securityTitle>
        <issuerName>Haleon plc</issuerName>
        <issuerPrincipalAddress>
          <com:street1>Building 5, First Floor, The Heights</com:street1>
          <com:city>Weybridge, Surrey</com:city>
          <com:stateOrCountry>X0</com:stateOrCountry>
          <com:zipCode>KT13 0NY</com:zipCode>
        </issuerPrincipalAddress>
        <commentText>Explanatory Note

The following constitutes Amendment No. 13 ("Amendment No. 13") to the Schedule 13D filed with the SEC by Pfizer on July 27, 2022, as amended by Amendment No. 1 on February 1, 2023, Amendment No. 2 on May 15, 2023, Amendment No. 3 on September 11, 2023, Amendment No. 4 on October 10, 2023, Amendment No. 5 on January 19, 2024, Amendment No. 6 on March 19, 2024, Amendment No. 7 on March 22, 2024, Amendment No. 8 on July 29, 2024, Amendment No. 9 on October 1, 2024, Amendment No. 10 on October 3, 2024, Amendment No. 11 on January 16, 2025 and Amendment No. 12 on January 21, 2025 (the "Schedule 13D"). This Amendment No. 13 amends and supplements the Schedule 13D as specifically set forth herein. Except as set forth herein, the Schedule 13D is unmodified. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.</commentText>
      </item1>
      <item2>
        <filingPersonName>No amendment to this Item is being made.</filingPersonName>
        <principalBusinessAddress>No amendment to this Item is being made.</principalBusinessAddress>
        <principalJob>No amendment to this Item is being made.</principalJob>
        <hasBeenConvicted>No amendment to this Item is being made.</hasBeenConvicted>
        <convictionDescription>No amendment to this Item is being made.</convictionDescription>
        <citizenship>No amendment to this Item is being made.</citizenship>
      </item2>
      <item3>
        <fundsSource>No amendment to this Item is being made.</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>Item 4 of the Schedule 13D is hereby supplemented as follows:

As previously disclosed, the Pfizer Relationship Agreement terminated following the closing of the January 2025 Secondary Offering and Pfizer no longer has the contractual right to nominate representative directors to be appointed to the Board. As a result, Mr. Supran stepped down from the Board on February 25, 2025.</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>The first and second paragraphs of Item 5 of the Schedule 13D are hereby superseded by the following paragraphs:

On February 25, 2025, Pfizer withdrew the Ordinary Shares underlying the restricted American Depositary Shares that it previously held under a restricted American Depositary Receipts facility with JPMorgan Chase Bank, N.A., as depositary.  The number of Ordinary Shares beneficially owned by Pfizer remains unchanged as a result of such withdrawal. As of the date of this Schedule 13D, Pfizer is the beneficial owner of 661,709,764 Ordinary Shares, which represents approximately 7.3% of the Issuer's outstanding Ordinary Shares. Pfizer's beneficial ownership is composed of (1) 661,709,764 Ordinary Shares held on behalf of Pfizer by Pfizer's nominee and (2) zero American Depositary Shares. The beneficial ownership percentage reported herein was calculated based on 9,054,145,714 Ordinary Shares outstanding as of January 31, 2025, as reported by the Issuer on its Form 6-K filed with the SEC on February 3, 2025.

The number of Ordinary Shares as to which the Reporting Person has the sole power to vote or direct the vote is 661,709,764. The number of Ordinary Shares as to which the Reporting Person shares the power to vote or direct the vote is zero. The number of Ordinary Shares as to which the Reporting Person has the sole power to dispose or direct the disposition is 661,709,764. The number of Ordinary Shares as to which the Reporting Person shares the power to dispose or direct the disposition is zero.</percentageOfClassSecurities>
        <numberOfShares>See (a).</numberOfShares>
        <transactionDesc>No amendment to this Item is being made.</transactionDesc>
        <listOfShareholders>No amendment to this Item is being made.</listOfShareholders>
        <date5PercentOwnership>No amendment to this Item is being made.</date5PercentOwnership>
      </item5>
      <item6>
        <contractDescription>No amendment to this Item is being made.</contractDescription>
      </item6>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Pfizer Inc.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Madelyn D. Purcell</signature>
          <title>Madelyn D. Purcell/Assistant Secretary</title>
          <date>02/27/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
